GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AUPH · Mar 31, 2022

Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-22-013439General Corporate

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-216.17% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

2265.97% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

121.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

98.82% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-175.18% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

58.36% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

32.48% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesSelf-history eligible

Mar 31, 20210/6 normalizedLevel 3 Jun 30, 20210/6 normalizedLevel 3 Sep 30, 20210/6 normalizedLevel 3 Dec 31, 20210/7 normalizedLevel 3 Mar 31, 20220/7 normalizedLevel 3 Jun 30, 20220/7 normalizedLevel 3 Sep 30, 20220/7 normalizedLevel 3 Dec 31, 20225/7 normalizedLevel 3 Mar 31, 20236/7 normalizedLevel 3 Jun 30, 20236/7 normalizedLevel 3 Sep 30, 20236/7 normalizedLevel 3 Sep 30, 20267/7 normalizedLevel 4

Period transition

What moved in the state?

Cash Generation Increased

Previous: -345.78%
Current: -216.17%
Delta: 129.61%

Growth Increased

Previous: -9.00%
Current: 2265.97%
Delta: 2274.98%

Inventory Pressure Increased

Previous: 42.38%
Current: 121.46%
Delta: 79.08%

Margin Increased

Previous: 97.61%
Current: 98.82%
Delta: 1.21%

Profitability Increased

Previous: -396.31%
Current: -175.18%
Delta: 221.13%

R And D Intensity Decreased

Previous: 112.13%
Current: 58.36%
Delta: -53.78%

Sbc Intensity Decreased

Previous: 68.51%
Current: 32.48%
Delta: -36.03%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AUPH Fundamental State →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH R_AND_D_INTENSITY_DECREASED →Transitioned To · AUPH SBC_INTENSITY_DECREASED →Transitioned To · AUPH Fundamental State →Transitioned To · AUPH CASH_GENERATION_INCREASED →Transitioned To · AUPH GROWTH_INCREASED →Transitioned To · AUPH INVENTORY_PRESSURE_INCREASED →Transitioned To · AUPH MARGIN_INCREASED →Transitioned To · AUPH PROFITABILITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.